4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors

Core Viewpoint - 4D Molecular Therapeutics (NASDAQ: FDMT) is considered an attractive investment opportunity for long-term investors with a high-risk tolerance, particularly in late 2025, given its current share price of $8.35 as of September 29 and its market capitalization [1] Company Summary - The company operates in the biotechnology sector, focusing on innovative therapeutic solutions [1] - The current share price indicates potential for growth, appealing to investors looking for long-term value [1] Investment Considerations - The investment is characterized by short-term volatility, which may be suitable for investors who can withstand such fluctuations [1] - The analysis suggests that the company may present a favorable risk-reward profile for those willing to invest in the biotechnology field [1]